Cargando…

Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases

Background: Although liver biopsy remains the gold standard for the diagnosis and the monitoring of liver disease, non-invasive biomarkers have been recently suggested to predict liver disease severity, progression, and response to therapy. We investigated multiple tissue and circulating markers of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bocci, Guido, Orlandi, Paola, Manca, Maria Laura, Rossi, Chiara, Salvati, Antonio, Brunetto, Maurizia Rossana, Solini, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604565/
https://www.ncbi.nlm.nih.gov/pubmed/36294318
http://dx.doi.org/10.3390/jcm11205985
_version_ 1784817846000287744
author Bocci, Guido
Orlandi, Paola
Manca, Maria Laura
Rossi, Chiara
Salvati, Antonio
Brunetto, Maurizia Rossana
Solini, Anna
author_facet Bocci, Guido
Orlandi, Paola
Manca, Maria Laura
Rossi, Chiara
Salvati, Antonio
Brunetto, Maurizia Rossana
Solini, Anna
author_sort Bocci, Guido
collection PubMed
description Background: Although liver biopsy remains the gold standard for the diagnosis and the monitoring of liver disease, non-invasive biomarkers have been recently suggested to predict liver disease severity, progression, and response to therapy. We investigated multiple tissue and circulating markers of angiogenesis in predicting the severity of biopsy-validated chronic liver diseases in patients with chronic hepatitis C virus (HCV) and in NAFLD/NASH patients. Methods: We studied samples from forty-six patients with HCV and/or NAFLD who underwent liver biopsy, liver ultrasonography, and liver stiffness measurement. Ishak and Brunt scores were calculated. Expression of selective genes and luminex analyses of 17 different circulating pro-angiogenic factors were performed. Results: The phenotype of NAFLD/NASH or HCV subjects was similar, except for insulin, which was expressed at higher levels in NAFLD/NASH patients. A Mann–Whitney test showed significant differences for the circulating levels of HB-EGF and for follistatin between HCV and NAFLD/NASH patients. In HCV patients, we found an inverse correlation between disease stage and BMP-9 and VEGF-A circulating levels, while in NASH/NAFLD direct correlations between stage and BMP-9 and VEGF-A circulating levels were noted. The K-means algorithm divided HCV and NASH/NAFLD patients in two clusters with significant differences between them. Logistic regression models showed a positive relationship with BMP-9 levels for NASH/NAFLD and with HB-EGF circulating concentrations for HCV. ROC analysis showed for BMP-9 > 1188 pg/mL a worse disease in NASH/NAFLD, whereas for HB-EGF < 61 pg/mL a higher severity of disease in HCV. Conclusion: Our data show that circulating biomarker profiles can identify the severity of chronic liver disease of NAFLD/NASH or HCV origin.
format Online
Article
Text
id pubmed-9604565
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96045652022-10-27 Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases Bocci, Guido Orlandi, Paola Manca, Maria Laura Rossi, Chiara Salvati, Antonio Brunetto, Maurizia Rossana Solini, Anna J Clin Med Article Background: Although liver biopsy remains the gold standard for the diagnosis and the monitoring of liver disease, non-invasive biomarkers have been recently suggested to predict liver disease severity, progression, and response to therapy. We investigated multiple tissue and circulating markers of angiogenesis in predicting the severity of biopsy-validated chronic liver diseases in patients with chronic hepatitis C virus (HCV) and in NAFLD/NASH patients. Methods: We studied samples from forty-six patients with HCV and/or NAFLD who underwent liver biopsy, liver ultrasonography, and liver stiffness measurement. Ishak and Brunt scores were calculated. Expression of selective genes and luminex analyses of 17 different circulating pro-angiogenic factors were performed. Results: The phenotype of NAFLD/NASH or HCV subjects was similar, except for insulin, which was expressed at higher levels in NAFLD/NASH patients. A Mann–Whitney test showed significant differences for the circulating levels of HB-EGF and for follistatin between HCV and NAFLD/NASH patients. In HCV patients, we found an inverse correlation between disease stage and BMP-9 and VEGF-A circulating levels, while in NASH/NAFLD direct correlations between stage and BMP-9 and VEGF-A circulating levels were noted. The K-means algorithm divided HCV and NASH/NAFLD patients in two clusters with significant differences between them. Logistic regression models showed a positive relationship with BMP-9 levels for NASH/NAFLD and with HB-EGF circulating concentrations for HCV. ROC analysis showed for BMP-9 > 1188 pg/mL a worse disease in NASH/NAFLD, whereas for HB-EGF < 61 pg/mL a higher severity of disease in HCV. Conclusion: Our data show that circulating biomarker profiles can identify the severity of chronic liver disease of NAFLD/NASH or HCV origin. MDPI 2022-10-11 /pmc/articles/PMC9604565/ /pubmed/36294318 http://dx.doi.org/10.3390/jcm11205985 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bocci, Guido
Orlandi, Paola
Manca, Maria Laura
Rossi, Chiara
Salvati, Antonio
Brunetto, Maurizia Rossana
Solini, Anna
Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases
title Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases
title_full Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases
title_fullStr Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases
title_full_unstemmed Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases
title_short Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases
title_sort predictive power of tissue and circulating biomarkers for the severity of biopsy-validated chronic liver diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604565/
https://www.ncbi.nlm.nih.gov/pubmed/36294318
http://dx.doi.org/10.3390/jcm11205985
work_keys_str_mv AT bocciguido predictivepoweroftissueandcirculatingbiomarkersfortheseverityofbiopsyvalidatedchronicliverdiseases
AT orlandipaola predictivepoweroftissueandcirculatingbiomarkersfortheseverityofbiopsyvalidatedchronicliverdiseases
AT mancamarialaura predictivepoweroftissueandcirculatingbiomarkersfortheseverityofbiopsyvalidatedchronicliverdiseases
AT rossichiara predictivepoweroftissueandcirculatingbiomarkersfortheseverityofbiopsyvalidatedchronicliverdiseases
AT salvatiantonio predictivepoweroftissueandcirculatingbiomarkersfortheseverityofbiopsyvalidatedchronicliverdiseases
AT brunettomauriziarossana predictivepoweroftissueandcirculatingbiomarkersfortheseverityofbiopsyvalidatedchronicliverdiseases
AT solinianna predictivepoweroftissueandcirculatingbiomarkersfortheseverityofbiopsyvalidatedchronicliverdiseases